RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ARYx Therapeutics Stock

ARYx Therapeutics ROA 2024

ARYx Therapeutics ROA

0

Ticker

ARYX

ISIN

US0433871094

In 2024, ARYx Therapeutics's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year.

ARYx Therapeutics Aktienanalyse

What does ARYx Therapeutics do?

ARYx Therapeutics Inc is a pharmaceutical company founded in 1997 and based in Fremont, California. The company focuses on developing innovative patented therapies for the treatment of heart diseases and other metabolic diseases. The company's business model is based on recognizing the need for new and more effective medications and focusing on the discovery and development of such therapies. ARYx Therapeutics relies on a network of experienced professionals and a rigorous research and development program. ARYx Therapeutics has several divisions, including the development of therapies for the treatment of cardiac arrhythmias, as well as metabolic diseases such as diabetes and hypercholesterolemia. In addition, the company has developed a range of products that interact with the body in innovative ways by activating or blocking specific receptors. ARYx Therapeutics' most well-known product is the antiarrhythmic drug Dronedaron. It is the first antiarrhythmic drug to receive the safety standards of the US Food and Drug Administration (FDA) and offers an effective, safe, and well-tolerated treatment for atrial fibrillation. Dronedaron is currently approved in Europe and the US and is used worldwide by doctors and hospitals as an important treatment option. Another successful product from ARYx Therapeutics is the therapeutic agent NTP-2007. It was developed to increase insulin sensitivity and improve blood sugar control in patients with type 2 diabetes. NTP-2007 utilizes a novel mechanism that enhances the effect of insulin in the body without lowering blood sugar levels. It is currently being tested in clinical trials and showing promising results. Another promising product from ARYx Therapeutics is the anesthetic Fexinidazole. It is an innovative anesthetic that works in a unique way in the body and ensures fast and effective anesthesia without causing negative side effects. Fexinidazole is currently being tested in clinical trials and could prove to be an important innovation in anesthesiology. Overall, ARYx Therapeutics has established itself as a leading company in the research and development of innovative therapies for the treatment of heart diseases and metabolic diseases. The company aims to meet the needs of patients and medical professionals and improve global healthcare by pushing the boundaries of science and technology in medicine. ARYx Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding ARYx Therapeutics's Return on Assets (ROA)

ARYx Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing ARYx Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider ARYx Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in ARYx Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about ARYx Therapeutics stock

What is the Return on Assets (ROA) of ARYx Therapeutics this year?

The Return on Assets (ROA) of ARYx Therapeutics is 0 undefined this year.

What was the ROA of ARYx Therapeutics compared to the previous year?

The ROA of ARYx Therapeutics has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of ARYx Therapeutics?

A high ROA is advantageous for investors of ARYx Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in ARYx Therapeutics?

A low ROA can be unfavorable for investors of ARYx Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of ARYx Therapeutics affect the company?

An increase in ROA of ARYx Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of ARYx Therapeutics impact the company?

A reduction in the ROA of ARYx Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of ARYx Therapeutics?

Some factors that can influence the ROA of ARYx Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of ARYx Therapeutics important for investors?

The ROA of ARYx Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can ARYx Therapeutics take to improve ROA?

To improve ROA, ARYx Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does ARYx Therapeutics pay?

Over the past 12 months, ARYx Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ARYx Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of ARYx Therapeutics?

The current dividend yield of ARYx Therapeutics is .

When does ARYx Therapeutics pay dividends?

ARYx Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ARYx Therapeutics?

ARYx Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ARYx Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ARYx Therapeutics located?

ARYx Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ARYx Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ARYx Therapeutics from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did ARYx Therapeutics pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of ARYx Therapeutics in the year 2023?

In the year 2023, ARYx Therapeutics distributed 0 USD as dividends.

In which currency does ARYx Therapeutics pay out the dividend?

The dividends of ARYx Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ARYx Therapeutics

Our stock analysis for ARYx Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ARYx Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.